243 related articles for article (PubMed ID: 17386275)
1. Ranibizumab according to need: a treatment for age-related macular degeneration.
Spaide R
Am J Ophthalmol; 2007 Apr; 143(4):679-80. PubMed ID: 17386275
[No Abstract] [Full Text] [Related]
2. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
3. Ranibizumab and stroke.
Ueta T; Yanagi Y; Tamaki Y; Yamaguchi T
Ophthalmology; 2010 Sep; 117(9):1860; author reply 1860-1. PubMed ID: 20816253
[No Abstract] [Full Text] [Related]
4. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
5. Effect of ranibizumab retreatment frequency on neurosensory retinal volume in neovascular amd.
Keane PA; Chang KT; Liakopoulos S; Jivrajka RV; Walsh AC; Sadda SR
Retina; 2009 May; 29(5):592-600. PubMed ID: 19289984
[TBL] [Abstract][Full Text] [Related]
6. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
8. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.
Schmidt-Erfurth U; Eldem B; Guymer R; Korobelnik JF; Schlingemann RO; Axer-Siegel R; Wiedemann P; Simader C; Gekkieva M; Weichselberger A;
Ophthalmology; 2011 May; 118(5):831-9. PubMed ID: 21146229
[TBL] [Abstract][Full Text] [Related]
10. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy.
Kumar A; Sahni JN; Stangos AN; Campa C; Harding SP
Br J Ophthalmol; 2011 Apr; 95(4):530-3. PubMed ID: 20937739
[TBL] [Abstract][Full Text] [Related]
12. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab.
Barbazetto I; Saroj N; Shapiro H; Wong P; Freund KB
Retina; 2010 Oct; 30(9):1376-85. PubMed ID: 20683380
[TBL] [Abstract][Full Text] [Related]
13. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
Sadda SR; Stoller G; Boyer DS; Blodi BA; Shapiro H; Ianchulev T
Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab.
Lucas RS; McKee HD; Lee LR
Ophthalmology; 2007 Feb; 114(2):400; author reply 400-1. PubMed ID: 17270701
[No Abstract] [Full Text] [Related]
15. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.
Rosenfeld PJ; Shapiro H; Tuomi L; Webster M; Elledge J; Blodi B;
Ophthalmology; 2011 Mar; 118(3):523-30. PubMed ID: 20920825
[TBL] [Abstract][Full Text] [Related]
16. The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system.
Spaide RF
Am J Ophthalmol; 2009 Jul; 148(1):1-3. PubMed ID: 19540983
[No Abstract] [Full Text] [Related]
17. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact.
Gupta OP; Shienbaum G; Patel AH; Fecarotta C; Kaiser RS; Regillo CD
Ophthalmology; 2010 Nov; 117(11):2134-40. PubMed ID: 20591490
[TBL] [Abstract][Full Text] [Related]
18. Controversies in the treatment of wet age-related macular degeneration.
Moreno SF; Paloma JB
Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
[No Abstract] [Full Text] [Related]
19. Macular hole following intravitreal ranibizumab injection for choroidal neovascular membrane caused by age-related macular degeneration.
Querques G; Souied EH; Soubrane G
Acta Ophthalmol; 2009 Mar; 87(2):235-7. PubMed ID: 19292858
[No Abstract] [Full Text] [Related]
20. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
Lai TY; Chan WM; Liu DT; Lam DS
Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
